Journal Mobile Options
Table of Contents
Vol. 120, No. 3, 1999
Issue release date: November 1999
Int Arch Allergy Immunol 1999;120:218–224
(DOI:10.1159/000024270)

Systemic Immunological Changes Induced by Administration of Grass Pollen Allergens via the Oral Mucosa during Sublingual Immunotherapy

Fanta C. · Bohle B. · Hirt W. · Siemann U. · Horak F. · Kraft D. · Ebner H. · Ebner C.
aInstitute of General and Experimental Pathology, University of Vienna, bAllergy Clinic Reumannplatz, Vienna, cDepartment of ENT, University of Vienna Medical School, Vienna, Austria

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Twenty–four patients suffering from grass pollen allergy underwent sublingual immunotherapy (SLIT) with standardized grass pollen extract for 1 year. In order to investigate immunological changes induced by the administration of allergens via the oral mucosa, the SLIT–spit method was applied. The cumulative dose of approximately 80 μg of major allergen (grass group 5 allergen), was relatively low. During the time of treatment, we could observe a significant increase in the levels of specific IgG and IgG4 antibodies. However, the titers of allergen–specific IgE antibodies showed a significant increase in the course of SLIT as well. Analyzing lymphoproliferative responses, a significant decrease in reactivity in response to stimulation with complete grass pollen extract (p = 0.001) and to recombinant Phl p 1 (a major allergen of timothy grass, p<0.001) could be observed, indicating the induction of immunological tolerance. Proliferative responses to a control antigen (tetanus toxoid) were not influenced by the treatment. At different time points during SLIT, allergen (Phl p 1)–specific T cell clones (TCC) were established from the peripheral blood of the patients. Cytokine production by allergen–stimulated T cells did not reveal any changes consistent with immune deviation, i.e. the ratio of Th1/Th2 TCC did not change during SLIT. In conclusion, we provide evidence that sublingual treatment leads to systemic changes in immunoreactivity to the administered allergen.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Norman P, Winkelwerder W, Lichtenstein L: Immunotherapy of hay fever with ragweed antigen E: Comparisons with whole extracts and placebo. J Allergy 1968;42:93–108.

    External Resources

  2. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302:265–269.
  3. Bousquet J, Lockey RF, Malling HJ: WHO Position Paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998;53(suppl).
  4. Wekkeli M, Rosenkranz A, Hippmann G, Jarisch R, Götz M: Systemic side–effects in immunotherapy of allergic diseases – a comparative study. Wien Klin Wochenschr 1989; 101:639–652.

    External Resources

  5. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ: Antihistamine premedication in specific cluster immunotherapy: A double–blind placebo–controlled study. J Allergy Clin Immunol 1996;97:1207–1213.

    External Resources

  6. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660–667.
  7. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson C: Oral tolerance in humans. J Immunol 1994;152:4663–4670.
  8. Weiner LW: Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335–343.
  9. Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H: A double–blind, placebo–controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309–313.
  10. Horak F, Stübner P, Berger UE, Marks B, Toth J, Jäger S: Immunotherapy with sublingual birch pollen extract. A short–term double–blind placebo study. Invest Allergol Clin Immunol 1998;8:165–171.
  11. Feliziani V, Lattuada G, Partimiani S, Dalláglio PP: Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: A double blind study. Allergol Immunopathol (Madr) 1995;23:224–230.
  12. Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double–blind study. Allergol Immunopathol (Madr) 1990;18:277–284.
  13. Scadding GK, Brostoff J: Low–dose sublingual therapy in patients with allergic rhinitis due to house dust mites. Clin Allergy 1986;16: 483–491.

    External Resources

  14. Bousquet J, Scheinmann P, Guinnepain MT, Perrin–Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, André C: Sublingual–swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: A double–blind, placebo–controlled study. Allergy 1999;54:249–260.
  15. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT: Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178:2123–2130.
  16. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA: Grass pollen immunotherapy inhibits allergen–induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing IFN–γ. J Allergy Clin Immunol 1996;97: 1356–1365.
  17. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K: Role of interleukin–10 in specific immunotherapy. J Clin Invest 1998;102:98–106.
  18. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O: Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27: 1007–1015.

    External Resources

  19. Birkner T, Rumpold H, Jarolim E, Ebner H, Breitenbach M, Svaril F, Scheiner O, Kraft D: Evaluation of immunotherapy–induced changes in specific IgE, IgG, and IgG–subclasses in birch pollen allergic patients by means of immunoblotting. Allergy 1989;45:418–425.
  20. Giannarini L, Maggi E: Decrease of allergen–specific T cell response induced by local nasal immunotherapy. Clin Exp Allergy 1998;28: 404–412.
  21. Schenk S, Breiteneder H, Susuani M, Najafian N, Laffer S, Duchene M, Valenta R, Fischer G, Scheiner O, Kraft D, Ebner C: T cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): Evidence for crossreacting and non–crossreacting T cell epitopes within grass group I allergens. J Allergy Clin Immunol 1995;96:686–696.
  22. Laffer S, Valenta R, Vrtala S, Susani M, VanRee R, Kraft D, Scheiner O, Duchene M: Complementary DNA cloning of the major allergen Phl p 1 from timothy grass (Phleum pratense); recombinant Phl p 1 inhibits IgE–binding to group 1 allergens from eight different grass species. J Allergy Clin Immunol 1994;94:689–698.
  23. Ebner C, Schenk S, Najafjan N, Siemann U, Steiner R, Fischer G, Hoffmann K, Szepfalusi S, Scheiner O, Kraft D: Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995;154:1932–1940.
  24. De Waal Malefyt R, Abrams J, Bennett B, Fidgor CG, DeVries JE: Interleukin 10 (IL–10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL–10 produced by monocytes. J Exp Med 1991;174: 1209–1220.
  25. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, DeVries JE, Roncarolo MG: A CD4+ T cell–subset inhibits antigen–specific T cell responses and prevents colitis. Nature 1997;389:737–742.
  26. Bellinghausen I, Metz G, Enk A, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin–10 production and a Th1–to–Th2 shift, and changes surface marker expression in venom–allergic subjects. Eur J Immunol 1997;27:1131–1139.
  27. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K: Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98–106.
  28. Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, Mistrello G, Canonica GW: Absorption and distribution kinetics of the major Paritaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997;100:122–129.
  29. Clavel R, Bousqet J, André C: Clinical efficacy of sublingual–swallow immunotherapy: A double–blind, placebo–controlled trial of a standardized five–grass–pollen extract in rhinitis. Allergy 1998;53:493–498.
  30. Voudras D, Syrigou E, Potamianou P, Carat F, Batard T, André C, Papageorgiou PS: Double–blind, placebo–controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53: 662–672.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50